ArticleFrontiers in oncology2026
Multiphasic CT-based multimodal deep learning model for predicting early hepatocellular carcinoma recurrence following liver transplantation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Leakage-Free Survival-Modelling Benchmark for Hepatocellular Carcinoma Recurrence After Liver Transplantation: Nested Cross-Validation Against the Milan Criteria.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to develop a multimodal deep learning (MD DL) model integrating multiphasic computed tomography (CT) with clinical and laboratory parameters to predict early recurrence of hepatocellular carcinoma (HCC) following liver transplantation. Methods: A retrospective analysis was conducted on 147 patients with HCC who underwent liver transplantation at Tianjin First Central Hospital between June 2014 and September 2022. Patients were categorized into recurrence ( Results: Independent risk factors for early recurrence included platelet count, alpha-fetoprotein levels > 400 ng/mL, ascites, arterial peritumoral enhancement, and portal vein tumor thrombus. The MD DL model achieved area under the curve values of 0.972, 0.885, and 0.985 in the training, validation, and test sets, respectively. These values indicated significantly superior predictive performance compared with other models (all Conclusion: The MD DL model integrating multiphasic CT and clinical parameters demonstrated high predictive accuracy for early recurrence of HCC after liver transplantation, with diagnostic performance exceeding that of conventional models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.